Previous 10 | Next 10 |
Marinus Pharmaceuticals ( NASDAQ: MRNS ) has entered into a revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5M upfront in return for payments based on U.S. net sales of ganaxolone, including the recently approved ZTALMY or...
$32.5 million upfront payment provides non-dilutive capital to further support commercialization of ZTALMY ® (ganaxolone); projected to extend cash runway into 2024 Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the developm...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2022 before the U.S. financ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s a scientific reality that people don’t operate well when they are anxious, but it also sets up an intriguing opportunity for sizzling stocks to buy. Essentially, with many investors panicking out of the...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that four abstracts have been accepted for poster presentation at upcoming medical meetings in October. Details...
Summary Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale of a priority review voucher and some additional cash flow from BARDA. ...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) said the Biomedical Advanced Research and Development Authority (BARDA) exercised its first contract option worth ~$12.3M, to support U.S. onshoring of manufacturing capabilities for seizure therapy ganaxolone active pharmaceutic...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Pr...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) on Monday said it had closed on the sale of a U.S. FDA voucher for $110M. The voucher, called the Rare Pediatric Disease Priority Review Voucher, entitles MRNS to a priority review from the agency and proceeds to carry out its d...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million. The $110...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...